Cara Therapeutics to Announce First Quarter 2021 Financial Results on May 10, 2021
04 May 2021 - 6:01AM
Cara Therapeutics, Inc. (Nasdaq: CARA), a biopharmaceutical
company focused on developing and commercializing new chemical
entities designed to alleviate pruritus by selectively targeting
peripheral kappa opioid receptors, today announced that the Company
will host a conference call and live audio webcast on Monday, May
10, 2021 at 4:30 p.m. ET to report first quarter 2021 financial
results and provide a corporate update.
To participate in the conference call, please
dial (855) 445-2816 (domestic) or (484) 756-4300 (international)
and refer to conference ID 5789617. A live webcast of the call can
be accessed under “Events & Presentations” in the News &
Investors section of the Company’s website at
www.CaraTherapeutics.com.
An archived webcast recording will be available
on the Cara website beginning approximately two hours after the
call.
About Cara Therapeutics
Cara Therapeutics is a clinical-stage
biopharmaceutical company focused on developing and commercializing
new chemical entities designed to alleviate pruritus by selectively
targeting peripheral kappa opioid receptors, or KORs. Cara is
developing a novel and proprietary class of product candidates, led
by KORSUVA™ (CR845/difelikefalin), a first-in-class KOR agonist
that targets the body’s peripheral nervous system, as well as
certain immune cells. In two Phase 3 trials, KORSUVA Injection has
demonstrated statistically significant reductions in itch intensity
and concomitant improvement in quality of life measures in
hemodialysis patients with moderate-to-severe chronic kidney
disease-associated pruritus (CKD-aP). The U.S. Food and Drug
Administration (FDA) has accepted and granted Priority Review for
the New Drug Application (NDA) for KORSUVA™ (difelikefalin)
solution for injection for the treatment of moderate-to-severe
pruritus in hemodialysis patients. The PDUFA target action date for
KORSUVA is August 23, 2021. Oral KORSUVA™ has completed Phase 2
trials for the treatment of pruritus in patients with CKD and AD
and is currently in Phase 2 trials in primary biliary cholangitis
and notalgia paresthetica patients with moderate-to-severe
pruritus.
The FDA has conditionally accepted KORSUVA™ as
the trade name for difelikefalin injection. CR845/difelikefalin is
an investigational drug product and its safety and efficacy have
not been fully evaluated by any regulatory authority.
MEDIA CONTACT:Claire LaCagnina6
Degrees315-765-1462clacagnina@6degreespr.com
INVESTOR CONTACT:Janhavi
MohiteStern Investor Relations,
Inc.212-362-1200janhavi.mohite@SternIR.com
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From Apr 2024 to May 2024
Cara Therapeutics (NASDAQ:CARA)
Historical Stock Chart
From May 2023 to May 2024